Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Brain Metastases Clinical Trial

— RadioCoBRIM  

Official title:

An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03430947
• Other study ID #: TUD-CoBRIM-67
• Secondary ID: 2017-000768-13
• Status: Terminated
• Phase: Phase 2
• Start date: July 1, 2018
• Est. completion date: February 10, 2023

Study information

• Verified date: September 2023
• Source: Technische Universität Dresden
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg once a day on days 1 - 21 of each 28-day treatment cycle until disease progression, drug toxicity or death.

The primary objective of this study is to determine the best overall response rate (BORR) in the brain. The extracranial BORR, intra- and extracranial duration of response, progression-free survival and overall survival, adverse events, quality of life and radiomics features predicting long-term local control of brain metastases and treatment-related toxicity will also be examined.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: February 10, 2023
• Est. primary completion date: February 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• Signed informed consent

• Female and male patients = 18 years of age

• Histologically confirmed metastatic melanoma (stage IV, per AJCC staging), carrying BRAF V600-mutation

• Performed SRS 14 ±7 days before baseline using a harmonized protocol in patients with at least one measurable intracranial target lesion for which the following criteria are met:

• Previously untreated (Lesions in previously irradiated area should not be selected)

• Largest diameter of = 0.5 but = 4 cm as determined by contrast-enhanced MRI and

• = 10 brain metastases

• ECOG performance status 0 - 2

• Life expectancy = 12 weeks

• Adequate bone marrow function as indicated by the following:

• ANC = 1500/µL,

• Platelets = 100,000/µL and

• Hemoglobin = 9 g/dL

• Adequate renal function, as indicated by creatinine = 1.5 x ULN

• Adequate liver function, as indicated by bilirubin < 1.5 x ULN and AST and ALT < 3 x ULN (documented liver metastases: AST and ALT < 5 x ULN)

• Adequate coagulation within 28 days prior to baseline visit

• Patients without therapeutic anticoagulation: INR or aPTT = 1.5 x ULN

• Patients receiving therapeutic anticoagulation: stable anticoagulation regimen and stable INR

• Able to swallow pills

Exclusion criteria

• Symptomatic brain metastases requiring immediate local interventions such as neurosurgery or radiosurgery

• Leptomeningeal disease (also synchronous with brain metastases)

• Prior therapy with BRAF or MEK inhibitors within 12 weeks prior to baseline visit (prior therapies for metastatic melanoma including chemo-, cytokine-, immuno-, biological and vaccine-therapy will be al-lowed) A period of at least 6 weeks must be observed between the last dose of ipilimumab and the first administration of the study treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1 (PD-L1) is allowed.

• Prior whole brain irradiation (Patients with prior local therapy of brain metas-tases are eligible)

• Patients receiving therapeutic steroids are not stable on corticoster-oids 2 weeks before SRS

• Active and uncontrolled infection

• Known HIV infection or active HBV or HCV infection

• Active HBV infection (chronic and acute), defined as having a posi-tive hepatitis B surface antigen (HBsAg) test at screening (past or resolved HBV infection, defined as negative HBsAg test and a posi-tive total hepatitis B core antibody test at screening, are eligible)

• Active HCV infection, defined as positive HCV antibody test and positive HCV RNA test at screening

• Intracranial radiation therapy within 14 days prior to SRS

• Extracranial radiation therapy within the last 14 days prior to baseline visit

• Treatment with strong CYP3A4/5 inhibitors (e.g. ketoconazole) and inducers (e.g. phenytoin, carbamazepine). (anticonvulsant levetiracetam is allowed; patient should be stable on levetiracetam for 2 weeks)

• Unresolved toxicity of National Cancer Institute Common Terminology Crite-ria for Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous anti-cancer therapy, except alopecia.

• Conditions that will interfere significantly with the absorption of drugs (e.g. Colitis ulcerosa)

• Inability to undergo MRI secondary to:

• Metal,

• Claustrophobia, or

• Gadolinium contrast allergy

• Previous malignancies active within the last 3 years, with the exception of locally curable cancers that have been treated to complete remis-sion or untreated stage I chronic lymphoid leukemia.

• Unwillingness or inability to comply with study and follow-up procedures

• Known hypersensitivity to any of the excipients of cobimetinib and vemuraf-enib

• The following foods/supplements are prohibited at least 7 days prior to initia-tion of and during study treatment:

• St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)

• Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)

• Patient is included in another interventional trial

• Use of any investigational or non-registered product within 4 weeks prior to baseline visit

• Woman of childbearing age with the exception they meet at least one of the following criteria:

• Post-menopausal,

• Sterilization,

• Consistently & correct application of contraceptives (Pearl Index < 1%),

• sexual abstinence, or

• vasectomy of the partner

• Pregnant or lactating women

• History, risk factor or retinal pathology that increases the risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology that is considered a risk factor for RVO or CSR, or a history of retinal detachment, central serous chorioretinopathy or reti-nal vein thrombosis. The risk factors for RVO are listed below:

• Uncontrolled glaucoma with intraocular pressures > 21 mm Hg,

• Serum cholesterol = Grade 2 (= 7.75 mmol/L),

• Hypertriglyceridemia = Grade 2 (= 3.42 mmol/L), Hyperglycemia (fasting) = Grade 2 (= 8.9 mmol/L).

• History of clinically significant cardiac dysfunction including:

• Myocardial infarction,

• Severe/unstable angina pectoris,

• Symptomatic congestive heart failure (NYHA stage = 2),

• cerebrovascular accident or transient ischemic attack within the previous 6 months,

• History of congenital long QT syndrome or mean QTcF > 450 msec or uncorrectable electrolyte abnormalities,

• Hypertension > Grade 2 not controlled by medications

• Left ventricular ejection fraction (LVEF) < 50%, or

• Uncontrolled arrhythmias

Related Conditions & MeSH terms

• BRAF V600 Mutation
• Brain Metastases
• Brain Neoplasms
• Malignant Melanoma Stage IV
• Melanoma
• Neoplasm Metastasis

Intervention

Drug:
• Vemurafenib
Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
• Cobimetinib
Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.

Locations

Country	Name	City	State
Germany	Technische Universität Dresden	Dresden
Germany	Ruprecht-Karls-University of Heidelberg, Faculty of Medicine	Heidelberg
Germany	Eberhard Karls University of Tübingen, University Medical Center	Tuebingen

Sponsors (1)

Lead Sponsor	Collaborator
Technische Universität Dresden

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best overall response rate in the brain	rate of patients with complete response or partial response (intracranial)	2 years
Secondary	Extracranial best overall response rate	rate of patients with complete response or partial response (extracranial)	2 years
Secondary	Best overall response rate calculated for the whole body tumor sites	rate of patients with complete response or partial response	2 years
Secondary	Intracranial duration of response	time from best overall response in the brain to first documentation of intracranial progression	2 years
Secondary	Extracranial duration of response	time from best extracranial overall response to first documentation of extracranial progression	2 years
Secondary	Progression-free survival	time from first dose of study treatment until progression	2 years
Secondary	Overall survival	time from first dose of study treatment until death due to any cause	2 years
Secondary	Incidence of adverse events	Adverse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; number of patients who withdraw from the study due to intolerable adverse events.	2 years
Secondary	Radiomics for long-term control of brain metastases	Radiomics features predictive of long-term local control of brain metastases using Magnetic Resonance Imaging	every 6 weeks up to 2 years
Secondary	Radiomics for intracranial Treatment-related toxicity	Radiomics features predicting treatment-related toxicity (e.g. radionecrosis, hemorrhage, edema) using Magnetic Resonance Imaging	every 6 weeks up to 2 years